08:00 , Feb 26, 2001 |  BC Week In Review  |  Company News

Aurelium, KS Biomedix deal

The companies will develop protein therapeutics to treat multi-drug resistant cancer. Aurelium will provide protein targets expressed on tumor cells that are resistant to a range of cancer drugs, and KSB will produce antibodies against...
08:00 , Feb 26, 2001 |  BioCentury  |  Finance

Ebb & Flow

Whispers of a deal between NASDAQ and EASDAQ are heating up in Europe, and market watchers told Ebb & Flow they anticipate news in the coming weeks on the creation of a pan-European trading platform...
08:00 , Feb 26, 2001 |  BioCentury  |  Finance

Ebb & Flow

Whispers of a deal between NASDAQ and EASDAQ are heating up in Europe, and market watchers told Ebb & Flow they anticipate news in the coming weeks on the creation of a pan-European trading platform...
08:00 , Feb 20, 2001 |  BC Extra  |  Company News

KSB, Aurelium in proteomics deal

KS Biomedix (LSE:KSB) and Aurelium BioPharma will develop protein therapeutics to treat multi-drug resistant cancer. Aurelium will provide protein targets expressed on tumour cells that are resistant to a range of anticancer drugs, and KSB...